Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer
- PMID: 17911008
- DOI: 10.1016/j.ejca.2007.08.018
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer
Abstract
Although trastuzumab, a recombinant humanised anti-ErbB2 antibody, is widely used in the treatment of breast cancer, neither its mechanism of action, nor the factors leading to resistance are fully understood. We have previously shown that antibody-dependent cellular cytotoxicity is pivotal in the in vivo effect of trastuzumab against JIMT-1, a cell line showing in vitro resistance to the antibody, and suggested that masking of the trastuzumab-binding epitope by MUC-4, a cell surface mucin, took place. Here, we further explored the role of masking of ErbB2 in connection with CD44 expression and synthesis of its ligand, hyaluronan. We show that high expression of CD44 observed in JIMT-1 cells correlates with ErbB2 downregulation in vivo, while siRNA-mediated inhibition of CD44 expression leads to decreased rate of trastuzumab internalisation and low cell proliferation in vitro. An inhibitor of hyaluronan synthesis, 4-methylumbelliferon (4-MU) significantly reduced the hyaluronan level of JIMT-1 cells both in vivo and in vitro leading to enhanced binding of trastuzumab to ErbB2 and increased ErbB2 down-regulation. Furthermore, the inhibitory effect of trastuzumab on the growth of JIMT-1 xenografts was significantly increased by 4-MU treatment. Our results point to the importance of the CD44-hyaluronan pathway in the escape of tumour cells from receptor-oriented therapy.
Similar articles
-
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.Cancer Res. 2005 Jan 15;65(2):473-82. Cancer Res. 2005. PMID: 15695389
-
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.Immunol Lett. 2006 Apr 15;104(1-2):146-55. doi: 10.1016/j.imlet.2005.11.018. Epub 2005 Dec 12. Immunol Lett. 2006. PMID: 16384610
-
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.Oncogene. 2007 Nov 1;26(50):7163-9. doi: 10.1038/sj.onc.1210528. Epub 2007 May 21. Oncogene. 2007. PMID: 17525746
-
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Semin Oncol. 1999. PMID: 10482195 Review.
-
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509. Nat Clin Pract Oncol. 2006. PMID: 16683005 Review.
Cited by
-
Epithelial cell dissemination and readhesion: analysis of factors contributing to metastasis formation in breast cancer.ISRN Oncol. 2012;2012:601810. doi: 10.5402/2012/601810. Epub 2012 Mar 12. ISRN Oncol. 2012. PMID: 22530147 Free PMC article.
-
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?MAbs. 2009 Jan-Feb;1(1):12-25. doi: 10.4161/mabs.1.1.7347. MAbs. 2009. PMID: 20046569 Free PMC article. Review.
-
Involvement of microRNAs in HER2 signaling and trastuzumab treatment.Tumour Biol. 2016 Oct 12. doi: 10.1007/s13277-016-5405-3. Online ahead of print. Tumour Biol. 2016. PMID: 27734339 Review.
-
Resistance to Trastuzumab.Cancers (Basel). 2022 Oct 19;14(20):5115. doi: 10.3390/cancers14205115. Cancers (Basel). 2022. PMID: 36291900 Free PMC article. Review.
-
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges.Cancers (Basel). 2023 Feb 10;15(4):1130. doi: 10.3390/cancers15041130. Cancers (Basel). 2023. PMID: 36831473 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous